Sangamo Therapeutics is a genomic medicine company conducting research & development across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. The optionality and diversity inherent to Sangamo’s technology platform enables us to design therapeutic approaches to resolve the underlying genetic causes of disease, using whichever technology is best suited to deliver that treatment.
Because Sangamo’s technology platforms are related, we are applying learnings across studies to optimize each individual platform and uncover research and development paths forward. Sangamo is best known for developing our proprietary gene editing technology, zinc finger nucleases (ZFNs). Our technology team continues to optimize ZFNs for the three key dimensions of genome editing: precision, efficiency, and specificity.
Epigenome editing - technology safer and reversible than CRISPR
Science - 01-Jun-2022
Leaves DNA sequence unaltered while retaining the ability to specifically home
Gene Therapies to Greatly Reduce the Incidence of Cardiovascular Disease
Fight Aging! - 09-Mar-2018
Gene therapy could disable genes that sustain levels of lipids in the bloodstream.
Number of cre...